P532: KINETICS AND PROGNOSTIC VALUE OF MEASURABLE RESIDUAL DISEASE (MRD) IN PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA (AML) TREATED WITH VENETOCLAX IN COMBINATION WITH HYPOMETHYLATING AGENTS.

• Carlos Jimenez-Vicente,
• Francesca Guijarro,
• Monica Lopez-Guerra,
• Ares Guardia-Torrelles,
• Alexandra Martínez Roca,
• Alex Bataller,
• Daniel Esteban,
• Albert Cortés,
• Inés Zugasti,
• Daniel Munarriz,
• Dolors Colomer,
• Marina Diaz-Beya,
• Jordi Esteve

Affiliations

Carlos Jimenez-Vicente

1 HOSPITAL CLINIC BARCELONA, HEMATOLOGY, BARCELONA, Spain,

Francesca Guijarro

2 UNIVERSITY OF BARCELONA, BARCELONA, Spain,

Monica Lopez-Guerra

3 HOSPITAL CLINIC BARCELONA, HEMATOPATHOLOGY, Barcelona, Spain,

Ares Guardia-Torrelles

1 HOSPITAL CLINIC BARCELONA, HEMATOLOGY, BARCELONA, Spain,

Alexandra Martínez Roca

1 HOSPITAL CLINIC BARCELONA, HEMATOLOGY, BARCELONA, Spain,

Alex Bataller

1 HOSPITAL CLINIC BARCELONA, HEMATOLOGY, BARCELONA, Spain,

Daniel Esteban

1 HOSPITAL CLINIC BARCELONA, HEMATOLOGY, BARCELONA, Spain,

Albert Cortés

1 HOSPITAL CLINIC BARCELONA, HEMATOLOGY, BARCELONA, Spain,

Inés Zugasti

1 HOSPITAL CLINIC BARCELONA, HEMATOLOGY, BARCELONA, Spain,

Daniel Munarriz

1 HOSPITAL CLINIC BARCELONA, HEMATOLOGY, BARCELONA, Spain,

Dolors Colomer

2 UNIVERSITY OF BARCELONA, BARCELONA, Spain,

Marina Diaz-Beya

1 HOSPITAL CLINIC BARCELONA, HEMATOLOGY, BARCELONA, Spain,

Jordi Esteve

1 HOSPITAL CLINIC BARCELONA, HEMATOLOGY, BARCELONA, Spain,